Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
To determine the antitumor activity of MKC-1 in patients with unresectable or metastatic
pancreatic cancer who have failed at least one prior chemotherapy regimen in either the
neoadjuvant, adjuvant, or first-line metastatic setting